This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Elanco Animal Health Incorporated (ELAN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 2.86% and 0.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Elanco (ELAN) This Earnings Season?
by Zacks Equity Research
Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
U.S. Physical Therapy (USPH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 3.17% and 1.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Healthcare Stocks Poised to Surpass Earnings Estimates in Q1
by Debasmita Chatterjee
Improved patient volumes, a diversified healthcare portfolio and various technological advancements are likely to favor first-quarter results of ELAN, DCGO and OMIC.
Why Elanco Animal Health Incorporated (ELAN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amedisys (AMED) Q1 Earnings Top Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 10.81% and 2.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 23.53% and 1.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 11.76% and 4.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVAH vs. ELAN: Which Stock Is the Better Value Option?
by Zacks Equity Research
AVAH vs. ELAN: Which Stock Is the Better Value Option?
Elanco Animal Health Incorporated (ELAN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 7.69% and 3.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Elanco (ELAN) Ahead of Earnings?
by Zacks Equity Research
Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Elanco Animal Health Incorporated (ELAN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: National Vision, DaVita, Elanco Animal Health, Henry Schein and Phibro Animal Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: National Vision, DaVita, Elanco Animal Health, Henry Schein and Phibro Animal Health
5 Probable MedTech Winners Post-COVID on Discounted PEG
by Zacks Equity Research
Here are some MedTech stocks with favorable PEG ratio, which are expected to provide gains in 2021.
Top Ranked Momentum Stocks to Buy for June 9th
by Zacks Equity Research
TITN, NVDA, GIII, and ELAN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 9, 2021.
Top Ranked Momentum Stocks to Buy for May 21st
by Zacks Equity Research
ARCB, CNR, ELAN, and OSK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 21, 2021
What's in Store for Intersect ENT's (XENT) Q1 Earnings?
by Zacks Equity Research
PROPEL and SINUVA are expected to have contributed to Intersect ENT's (XENT) first-quarter revenues.
Elanco Animal Health Incorporated (ELAN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 60.87% and 7.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Elanco (ELAN)
by Zacks Equity Research
Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Healthcare Stock Q1 Earnings Due on May 7: ELAN, MD, MODV
by Sapna Bagaria
Varied companies across the vast healthcare space might have been affected differently by the COVID crisis during the first quarter.
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Elanco Animal Health Incorporated (ELAN)
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.